Baxter Bros Inc. Cuts Stock Position in Stryker Co. (NYSE:SYK)

Baxter Bros Inc. decreased its position in shares of Stryker Co. (NYSE:SYK) by 3.6% in the fourth quarter, HoldingsChannel reports. The fund owned 3,238 shares of the medical technology company’s stock after selling 120 shares during the quarter. Baxter Bros Inc.’s holdings in Stryker were worth $1,166,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker in the 4th quarter worth $25,000. Dunhill Financial LLC boosted its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Rakuten Securities Inc. grew its stake in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at about $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker in the 4th quarter worth approximately $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. Stifel Nicolaus raised their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Citigroup reaffirmed a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Barclays increased their price objective on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Truist Financial lifted their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Price Performance

Stryker stock opened at $374.43 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company’s fifty day moving average price is $384.55 and its 200 day moving average price is $374.24. The stock has a market capitalization of $142.87 billion, a P/E ratio of 48.25, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.